DOCSLIB.ORG

Ethicon, Inc. Pelvic Repair Systems Products Liability Litigation, Master File No

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ethicon, Inc. Pelvic Repair Systems Products Liability Litigation, Master File No Case 2:12-cv-05201 Document 320 Filed 08/04/14 Page 1 of 25 PageID #: 13901 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF WEST VIRGINIA AT CHARLESTON IN RE: ETHICON, INC. PELVIC REPAIR Master File No. 2:12-MD-02327 SYSTEM PRODUCTS LIABILITY MDL No. 2327 LITIGATION JOSEPH R. GOODWIN THIS DOCUMENT RELATES TO: U.S. DISTRICT JUDGE Jo Beth Huskey, et al. v. Johnson & Johnson, et al. Case No.: 2:12-cv-05201 [PROPOSED] JOINT PRETRIAL ORDER In accordance with Local Rule of Civil Procedure 16.7(b) and Rules 16 and 26 of the Federal Rules of Civil Procedure, and pursuant to Pretrial Order No. 127, Plaintiff Jo Huskey (“Plaintiff”) and Defendants Ethicon, Inc. and Johnson & Johnson (“Ethicon”), by their undersigned counsel, hereby respectfully submit the following [Proposed] Joint Pretrial Order for the Court’s consideration: I. PRETRIAL DISCLOSURES REQUIRED BY FEDERAL RULE OF CIVIL PROCEDURE 26(A)(3) AND OBJECTIONS THERETO A. Witnesses each party expects to present and may call if the need arises 1. Names of witnesses Plaintiff expects to present at trial: The final list of witnesses that Plaintiffs will present at trial is dependent on several factors, including but not limited to any further pre-trial rulings by the court; Plaintiffs’ ability to present certain witnesses whom they do not control for live testimony; and the Court’s time limitations: i. Jo Huskey ii. Allan Huskey iii. Dr. Bruce Rosenzweig iv. Dr. Jerry Blaivas Case 2:12-cv-05201 Document 320 Filed 08/04/14 Page 2 of 25 PageID #: 13902 v. Dr. Erin Carey vi. Scott Guelcher, Ph.D. vii. David Epperly 2. Names of witnesses Plaintiff may call if the need arises at trial: i. Gretchen Dean PT ii. Nancy Davidson iii. Dr. John Steege iv. Russell Dunn, Ph.D. v. Abhay Pandit, Ph.D. vi. Any witness called by the Defendant 3. Ethicon’s objections, if any, to Plaintiff’s witness list: Ethicon objects to any witness listed by Plaintiff testifying to that which is beyond what is set forth in their report and insofar as said witness’s testimony has been excluded by the Court’s rulings on Ethicon’s motions to exclude or in limine motions. In addition, Ethicon objects to Plaintiff calling any fact witness or treating physician not previously identified or made available for deposition. 4. Names of witnesses Ethicon expects to present at trial: The final list of witnesses that Ethicon will present at trial is dependent on several factors, including (a) the witnesses that Plaintiff presents during her case-in-chief, (b) the Court’s rulings on motions, and (c) the trial schedule and availability of Ethicon’s witnesses. Ethicon also reserves the right to call any witness listed by Plaintiff. Subject to those considerations, Ethicon presently expects to call the following witnesses at trial: i. Daniel Sexton, M.D. ii. Christina Pramudji, M.D. iii. Plaintiff’s treating physicians: a. Gretchen Byrkit, M.D. b. Colleen Fitzgerald, M.D. c. James Harms, M.D. d. Elizabeth Mueller, M.D. e. Dele Ogunleye, M.D. f. Derin Rominger, M.D. g. Kenneth Schoenig, M.D. h. Bryan Yocks, M.D. iv. Plaintiff’s coworkers and friends: a. Bryan Jasker b. Ruth Teel c. Terry Ward v. Ethicon employees: a. Piet Hinoul, M.D. b. Axel Arnaud, M.D. Case 2:12-cv-05201 Document 320 Filed 08/04/14 Page 3 of 25 PageID #: 13903 5. Names of witnesses Ethicon may call if the need arises at trial: i. Laura Angelini ii. Thomas Barbolt, Ph.D., DABT iii. Thomas A. Barocci, Ph.D. iv. Boris Batke v. Catherine Beath vi. Dan Burkley vii. Peter Cecchini viii. Meng Chen, M.D. ix. Judi Gauld x. James Hart, M.D. xi. Matthew Henderson xii. Kimberly Hunsicker xiii. Joerg Holste xiv. Michelle Irvin xv. Richard Isenberg, M.D. xvi. Harry Johnson, M.D. xvii. Gregory Jones xviii. Scott Jones xix. Gene Kammerer xx. Brian Kanerviko xxi. Aaron Kirkemo, M.D xxii. Dan Lamont xxiii. Reynaldo Librojo xxiv. Susan Lin xxv. Bryan Lisa xxvi. Brian Luscombe xxvii. Brett Marshall xxviii. Codi Marshall xxix. Clint Marshall xxx. Jim Mittenthal xxxi. Charles Nager, M.D. xxxii. Sean O’Bryan xxxiii. Charlotte Owens, M.D. xxxiv. Jennifer Paine xxxv. Paul Parisi xxxvi. David Robinson, M.D. xxxvii. Mark Schneider xxxviii. Daniel Smith xxxix. Shelby Thames, Ph.D. xl. Timothy Ulatowski, M.S xli. David Weber, M.D., M.P.H. xlii. Martin Weisberg, M.D. xliii. Mark Yale xliv. Wenxin Zheng, M.D. Case 2:12-cv-05201 Document 320 Filed 08/04/14 Page 4 of 25 PageID #: 13904 xlv. Any other treating physician or health care provider identified in the medical records for plaintiff Jo Huskey. 6. Plaintiff’s objections, if any, to Ethicon’s witness list: Pursuant to Pretrial Order #127, Plaintiffs will serve their objections to Ethicon’s witness list by August 14, 2014. Plaintiffs object to any witness listed by Ethicon testifying to that which is beyond what is set forth in their report and insofar as said witness’s testimony has been excluded by the Court’s rulings on Ethicon’s motions to exclude or in limine motions. In addition, Plaintiffs object to Ethicon calling any fact witness or treating physician not previously identified or made available for deposition. Finally, Plaintiffs object to testimony from physicians who treated Mrs. Huskey for conditions not relevant to her TVT-O and resulting pelvic pain, or conditions that Ethicon’s experts have been precluded from testifying about at trial. B. Designation of witnesses whose testimony is expected to be presented by means of deposition (whether videotaped or otherwise) 1. Plaintiff As with live testimony, the Plaintiffs’ final list for presentation by deposition will depend on several factors, including but not limited to any further pre-trial rulings by the court, including clarifications of rulings already made; Plaintiffs’ ability to present certain witnesses whom they do not control for live testimony; and the Court’s time limitations: i. Dr. Gretchen Byrkit ii. Dr. Sohail Siddique iii. Gretchen Dean PT iv. Nancy Davidson v. Dr. Derin Rominger vi. Michelle Irvin vii. Bryan Jasker viii. LauraAngelini ix. Thomas Barbolt, Ph.D., DABT x. Dr. Meng Chen xi. Dr. James Hart xii. Brigette Helhammer xiii. Dr. Piet Hinoul xiv. Joerg Holste, DVM, Ph. D. xv. Dr. Richard Isenberg xvi. Dr. Aaron Kirkemo xvii. Dr. Bernd Klosterhalfen xviii. Dr. David Robinson xix. Daniel Smith xx. Dr. Martin Weisberg 2. Ethicon Case 2:12-cv-05201 Document 320 Filed 08/04/14 Page 5 of 25 PageID #: 13905 The final list of witnesses that Ethicon will present at trial via deposition is dependent on several factors, including (a) the witnesses that Plaintiff present during her case-in-chief, whether live or by deposition, (b) the Court’s rulings on motions, (c) the Court’s rulings on deposition designations, and (d) the trial schedule and availability of Ethicon’s witnesses. Ethicon reserves the right to designate deposition testimony for any witness presented at trial by the Plaintiff or whose deposition is played by the Plaintiff. Ethicon also reserves the right to call via deposition any witness listed by Plaintiff. Subject to those considerations, Ethicon may call the following witnesses at trial via deposition: i. Peter Cecchini ii. Jim Hart, M.D. iii. Kim Hunsicker iv. Richard Isenberg, M.D. v. Gene Kammerer vi. Aaron Kirkemo, M.D. vii. Dan Lamont viii. James Mittenthal ix. Charles Nager, M.D. x. Sean O’Bryan xi. Charlotte Owens xii. Gretchen Byrkit, M.D. xiii. Colleen Fitzgerald M.D. xiv. James Harms, M.D. xv. Bryan Jasker xvi. Elizabeth Mueller, M.D. xvii. Dele Ogunleye, M.D. xviii. Derin Rominger, M.D. xix. Kenneth Schoenig, M.D. xlvi. Ruth Teel xlvii. Terry Ward xlviii. Bryan Yocks, M.D. C. Exhibits each party expects to offer, may offer if the need arises, and objections thereto 1. Plaintiff expects to offer or utilize the exhibits and/or documents identified in the accompanying Attachment A. 2. Ethicon’s objections to Plaintiff’s exhibit list will be provided on August 18, 2014, as provided in PTO #122. 3. Ethicon expects to offer or utilize the exhibits and/or documents identified in the accompanying Attachment B. This list does not include medical literature or similar documents and materials that Ethicon may use with the appropriate witnesses such as learned treatises. Case 2:12-cv-05201 Document 320 Filed 08/04/14 Page 6 of 25 PageID #: 13906 4. Ethicon may offer if the need arises the exhibits and/or documents identified in the accompanying Attachment C. This list includes medical literature and similar documents and materials that Ethicon may use with the appropriate witnesses such as learned treatises. 5. Plaintiffs’ objections to Ethicon’s exhibit list will be provided on August 18, 2014, as provided in PTO #122. II. CONTESTED ISSUES OF LAW REQUIRING A RULING BEFORE TRIAL A. By Plaintiff 1. Any motions in limine or other evidentiary pretrial motions not yet filed. 2. Plaintiffs’ Motion to Permit Live Trial Testimony Via Contemporaneous Transmission B. By Ethicon 1. Defendants’ Omnibus Motions in Limine (Huskey Doc. 282) 2. Defendants’ Motion to Exclude Evidence of Spoliation (Huskey Doc. 274) 3. Defendants’ Motion to Limit Testimony of Erin Teeter Carey (Huskey Doc. 275) 4. Defendants’ Motion to Exclude Testimony by Scott Guelcher, Ph.D. in Reliance on Documents Identified in his Supplemental Reliance List Served August 1, 2014 and to Preclude Testimony other than Those Opinions Contained in Dr. Guelcher’s Expert Report Served February 21, 2014 (Huskey Doc. 314) 5. Defendants’ Motion to Exclude Testimony by Bruce Rosenzweig, M.D., on Matters Contained in his Fourth Supplemental Expert Report Served July 31, 2014 and Accompanying Reliance List (Huskey Doc.
Load more

Recommended publications
  • Get to the Heart of Pain Relief
    Get to the heart of pain relief Explain why analgesic choice matters to patients with, or at risk for, cardiovascular disease Counseling tips | Dosage | Savings Analgesic considerations that matter to the heart Reinforce your TYLENOL® recommendation to patients with, or at risk for, cardiovascular disease with these counseling tips: TYLENOL® won’t increase the risk of heart attack, heart failure, or stroke the way ibuprofen or naproxen sodium can1 TYLENOL® won’t interfere with aspirin heart therapy the way ibuprofen can2 TYLENOL® won’t increase blood pressure like NSAIDs sometimes can3,4 TYLENOL® won’t interfere with certain high blood pressure medications, such as diuretics and ACE inhibitors, the way NSAIDs sometimes can3,4 Order patient education, samples, and coupons at TylenolProfessional.com Not a member? Register today! The efficacy and safety of TYLENOL® at 4000 mg/day are well established. Healthcare professionals may exercise their discretion and recommend up to 4000 mg. Dosage for Adults Recommended dose from your healthcare professional: mg/day TYLENOL® Regular Strength Active ingredient: acetaminophen 325 mg (per tablet) Use only as directed. DOSE & FREQUENCY DAILY LIMIT 2 tablets every 4 to 6 hours Do not take more than 10 tablets while symptoms last in 24 hours, unless directed by your doctor TYLENOL® Extra Strength Active ingredient: acetaminophen 500 mg (per caplet) Use only as directed. DOSE & FREQUENCY DAILY LIMIT 2 caplets every 6 hours while Do not take more than 6 caplets symptoms last in 24 hours, unless directed by your doctor TYLENOL® 8 HR Arthritis Pain Active ingredient: acetaminophen 650 mg (per extended-release caplet) Use only as directed.
    [Show full text]
  • Learner Notification International Society for Heart & Lung
    Learner Notification International Society for Heart & Lung Transplantation (ISHLT) 41st Annual Meeting & Scientific Sessions Virtual Experience April 24 – 28, 2021 Live Virtual Acknowledgement of Financial Commercial Support Abbott Medtronic United Therapeutics Acknowledgement of In-Kind Commercial Support No in-kind commercial support was received for this educational activity. Satisfactory Completion Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety as partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement. Physicians (ACCME) The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Statement - ISHLT designates this live virtual activity for a maximum of 32.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Amedco LLC and ISHLT. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Nurses (ANCC) - Credit Designation Statement - Amedco LLC designates this live virtual activity for a maximum of 32.00 ANCC contact hours. Pharmacists (ACPE) - Credit Designation Statement - Amedco LLC designates this live virtual activity for a maximum of 32.00 knowledge-based CPE contact hours.
    [Show full text]
  • 2015 Annual Report
    ANNUAL REPORT 2015 MARCH 2016 TO OUR SHAREHOLDERS ALEX GORSKY Chairman, Board of Directors and Chief Executive Officer This year at Johnson & Johnson, we are proud this aligned with our values. Our Board of WRITTEN OVER to celebrate 130 years of helping people Directors engages in a formal review of 70 YEARS AGO, everywhere live longer, healthier and happier our strategic plans, and provides regular OUR CREDO lives. As I reflect on our heritage and consider guidance to ensure our strategy will continue UNITES & our future, I am optimistic and confident in the creating better outcomes for the patients INSPIRES THE long-term potential for our business. and customers we serve, while also creating EMPLOYEES long-term value for our shareholders. OF JOHNSON We manage our business using a strategic & JOHNSON. framework that begins with Our Credo. Written OUR STRATEGIES ARE BASED ON over 70 years ago, it unites and inspires the OUR BROAD AND DEEP KNOWLEDGE employees of Johnson & Johnson. It reminds OF THE HEALTH CARE LANDSCAPE us that our first responsibility is to the patients, IN WHICH WE OPERATE. customers and health care professionals who For 130 years, our company has been use our products, and it compels us to deliver driving breakthrough innovation in health on our responsibilities to our employees, care – from revolutionizing wound care in communities and shareholders. the 1880s to developing cures, vaccines and treatments for some of today’s most Our strategic framework positions us well pressing diseases in the world. We are acutely to continue our leadership in the markets in aware of the need to evaluate our business which we compete through a set of strategic against the changing health care environment principles: we are broadly based in human and to challenge ourselves based on the health care, our focus is on managing for the results we deliver.
    [Show full text]
  • Drug Information Center Highlights of FDA Activities
    Drug Information Center Highlights of FDA Activities – 9/1/20 – 9/30/20 FDA Drug Safety Communications & Drug Information Updates: Efficacy & Safety Concerns for Atezolizumab in Combination with Paclitaxel 9/8/20 The FDA alerted health care professionals and patients that a clinical trial evaluating atezolizumab plus paclitaxel in patients with previously untreated inoperable locally advanced or metastatic triple negative breast cancer that the drug combination was not effective. The combination of atezolizumab with another paclitaxel formulation, paclitaxel protein‐bound, is currently approved for use in adult patients with metastatic triple negative breast cancer, but this continued approval may be contingent on the results of additional studies. Paclitaxel should NOT be used as a replacement for paclitaxel protein bound in clinical practice. Electronic Expanded Access Requests 9/23/20 The FDA announced that the Reagan‐Udall Foundation has launched Expanded Access eRequest, a tool to submit expanded access requests for individual patient expanded access for drugs and biologics in non‐emergency settings. The tool allows auto population of forms, uploading of relevant documents, links to resources for physicians, patients, and caregivers, and secure application submission to the FDA. Benzodiazepine Drug Class: Drug Safety Communication ‐ Boxed Warning Update 9/23/20 The FDA is requiring the Boxed Warning be updated for all benzodiazepines to address serious risks of abuse, addiction, physical dependence, and withdrawal across the medication class. Changes are also being incorporated in the Medication Guides, and other sections of the prescribing information including the Warnings and Precautions, Drug Abuse and Dependence, and Patient Counseling Information sections. Diphenhydramine (Benadryl): Serious Problems with High Doses 9/24/20 The FDA issued a warning that taking higher than recommended doses of the common OTC allergy medication diphenhydramine (Benadryl) can lead to serious heart problems, seizures, coma, or even death.
    [Show full text]
  • United States District Court for the Central District Of
    Case 2:18-cv-09655 Document 1 Filed 11/15/18 Page 1 of 38 Page ID #:1 SIMMONS HANLY CONROY LLC 1 Crystal Foley (SBN 224627) 2 [email protected] 100 N. Sepulveda Blvd., Suite 1350 3 Los Angeles, CA 90245 4 Phone: (310) 322-3555 5 Mitchel M. Breit (pro hac vice 6 forthcoming) [email protected] 7 112 Madison Avenue 8 New York, New York 10016-7416 Phone: (212) 784-6400 9 10 Attorneys for Plaintiff 11 12 UNITED STATES DISTRICT COURT FOR THE CENTRAL DISTRICT OF CALIFORNIA 13 WESTERN DIVISION 14 TOYA EDWARDS on behalf of Case No.: ____________________2:18-cv-9655 15 herself and all others similarly 16 situated, Plaintiff, CLASS ACTION COMPLAINT 17 v. 18 DEMAND FOR JURY TRIAL WALMART, INC. 19 20 Defendant. 21 CLASS ACTION COMPLAINT 22 Plaintiff Toya Edwards individually and on behalf of all others similarly 23 situated, brings this action against Defendant Walmart, Inc. (“Walmart”). The 24 following allegations are based upon personal knowledge as to Plaintiff’s own 25 conduct, the investigation of counsel, and upon information and belief as to the acts 26 of others. 27 28 1 CLASS ACTION COMPLAINT Case 2:18-cv-09655 Document 1 Filed 11/15/18 Page 2 of 38 Page ID #:2 1 INTRODUCTION 2 1. Walmart is the world’s largest retail company operating thousands of 3 retail stores worldwide. 4 2. Walmart stores sell all types of products to the American public, 5 including toys, groceries, sports and outdoor equipment, electronics, home goods, 6 school supplies, apparel, cosmetics, health and wellness products, and many more.
    [Show full text]
  • Mcneil Consumer : Mdl No
    IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA IN RE: MCNEIL CONSUMER : MDL NO. 2190 HEALTHCARE, ET AL., MARKETING : AND SALES PRACTICES LITIGATION : : Applies to: : ALL ACTIONS : MEMORANDUM McLaughlin, J. July 13, 2012 This multidistrict litigation arises out of quality control problems at the defendants’ facility manufacturing over- the-counter healthcare products in Fort Washington, Pennsylvania, which led to a series of recalls of those products. The named plaintiffs assert claims for economic loss on behalf of a putative nationwide class against Johnson & Johnson (“J&J”), McNeil Consumer Healthcare (“McNeil”), and four of their executives. The plaintiffs allege that they overpaid for the defendants’ products as a result of the recalls and the defendants’ scheme to conceal or downplay the scope of the quality control problems. The defendants, who have offered a coupon or cash refund to consumers who purchased recalled drugs, have moved to dismiss the operative complaint, and assert that the named plaintiffs lack constitutional standing and have not met the applicable pleading standard. The Court will grant the defendants’ motion because the plaintiffs have not pled facts that show a cognizable injury in fact, which is required to confer Article III standing. I. Procedural Background This litigation resulted from the consolidation of ten individual actions filed around the country. Haviland v. McNeil Consumer Healthcare, No. 10-2195, was filed in this Court on May 12, 2010, asserting economic injuries arising out of the April 30, 2010 recall of over-the-counter children’s drugs by McNeil, a part of the J&J “Family of Companies.” Eight additional cases, also arising out of the April 2010 recall, were filed in district courts around the country.1 All cases asserted claims for economic injury only, with the exception of Rivera v.
    [Show full text]
  • Approved Prenatal Medications Pain Medications • Tylenol
    Approved Prenatal Medications Pain Medications Tylenol (acetaminophen) for minor aches and pains, headaches. (Do not use: Aspirin, Motrin, Advil, Aleve, Ibuprofen.) Coughs/Colds Robitussin (Cough) Robitussin DM (non-productive cough) DO NOT USE TILL OVER 12 WEEKS Secrets and Vicks Throat Lozenges Mucinex Sore Throat Chloraseptic spray Saline Gargle Sucrets and Vicks Throat Lozenges Antihistamines/Allergies Zyrtec Claritin Benadryl Dimetapp Insomnia Benadryl Unison Hemorrhoids Preparation H Tucks Anusol Diarrhea Imodium (1-2 doses- if it persists please notify the office) BRAT diet (bananas, rice, applesauce, toast) Lice RID (only!) DO NOT USE Kwell Itching Benadryl Calamine or Caladryl Lotion Hydrocortisone cream Heartburn, Indigestion, Gas Tums Gas-X Mylanta Pepcid Maalox Zantac *DO NOT USE PEPTO BISMOL- it contains aspirin Decongestants Sudafed Robitussin CF- Only if over 12 weeks Tavist D Ocean Mist Nasal Spray (saline solutions) Nausea Small Frequent Meals Ginger Ale Vitamin B6 Sea Bands Yeast Infections Monistat Mycolog Gyne-lotrimin Toothache Orajel May see dentists, have cavity filled using Novocain or lidocaine, have x-rays with double lead shield, may have antibiotics in the Penicillin family (penicillin, amoxicillin) Sweetners- all should be consumed in moderation with water being consumed more frequently Nutrisweet (aspartame) Equal (aspartame) Splenda (sucralose) Sweet’n Low (saccharin) *note avoid aspartame if you have phenylketonuria (PKU) Constipation Colace Fibercon Citrucel Senokot Metamucil Milk of Magnesia Fiberall Miralax Eczema Hydrocortisone Cream Medications to AVOID Accurate Lithium Paxil Ciprofloxacin Tetracycline Coumadin Other Chemicals to AVOID Cigarettes Alcohol Recreational Drugs: marijuana, cocaine, ecstasy, heroin .
    [Show full text]
  • Over-The-Counter (OTC) Medications Applies To: Tufts Health Ritogether and Tufts Health Together*
    Over-the-Counter (OTC) Medications Applies to: Tufts Health RITogether and Tufts Health Together* As communicated in the November 1, 2018 Provider Update, the following changes are effective for fill dates on or after January 1, 2019. As a result of this change, some OTC medications will require prior authorization in certain circumstances as outlined below: Brand-Name OTC Medication Has a Covered Interchangeable Generic Version Available Afrin No Drip Advil capsule Advil tablet Advil PM tablet Afrin Nasal Spray Original nasal solution Afrin No Drip Aveeno Oatmeal Severe nasal Aleve tablet Baciguent ointment Benadryl capsule Bath Pak Treatment solution Benadryl Allergy Benadryl Allergy Benadryl Allergy Benadryl Extra Benefiber powder tablet capsule Liquid Strength cream Caltrate 600 +D Centrum Silver Betadine Swabstick Caltrate + D tablet Centrum liquid Plus Minerals tablet tablet Centrum Silver Centrum Ultra Men’s Children’s Advil Centrum tablet Cheracol-D syrup Adult 50+ tablet tablet suspension Children’s Benadryl Citracal Calcium + Children’s Benadryl Children’s Tylenol Chlor-Trimeton Allergy chewable D Slow Release Allergy liquid suspension syrup tablet tablet Citrucel Fiber Claritin-D 12 hour Claritin-D 24 hour Clear Cough Liquid Citrucel tablet Laxative powder tablet tablet PM Dimetapp DM Dex4 Fast Acting Dimetapp Cold and Colace capsule Conceptrol 4% gel Cough and Cold Glucose liquid Allergy elixir elixir Dristan nasal spray Dulcolax tablet D-Vi-Sol liquid Ecotrin tablet Evac powder Ex-Lax chewable Gas-X chewable Feosol tablet
    [Show full text]
  • Johnson & Johnson 1999 EPS Rose 13.8% on Sales Increase of 14.5
    Johnson & Johnson 1999 EPS Rose 13.8% on Sales Increase of 14.5% Fourth Quarter EPS Rose 12.0% on Sales Increase of 6.3% NEW BRUNSWICK, N.J., Jan. 25 -- Johnson & Johnson (NYSE: JNJ - news) today announced sales for the fourth quarter of $6.9 billion, an increase of 6.3% over sales of $6.5 billion for the same period last year. Domestic sales were up 9.2% while international sales increased 2.9%. Excluding the impact of negative currency, international sales growth for the fourth quarter of 1999 was 10.2%. Worldwide sales for the year 1999 were a record $27.5 billion, an increase of 14.5% over 1998 sales of $24.0 billion. Excluding special charges, earnings per share in the fourth quarter of 1999 were $.56, an increase of 12.0% compared to $.50 for the same period in 1998. The special charges include costs associated with the Centocor merger in 1999 and the reconfiguration of the worldwide manufacturing network and in-process research and development charges in 1998. Excluding these charges, earnings per share were $2.97 for the year, compared with $2.61 per share in 1998, an increase of 13.8%. For the fourth quarter of 1999, including the special charges, the company reported earnings per share of $.53 compared with $.07 for the same period in 1998. For the year, earnings per share were $2.94, compared with $2.12 per share in 1998. Excluding special charges, consolidated net earnings for the fourth quarter were $796 million, compared with $712 million for the same period a year ago, an increase of 11.8%.
    [Show full text]
  • Benadryl (Diphenhydramine) Dosing Chart
    1084 Cromwell Avenue Rocky Hill, CT 06067 (860) 721-7561 – Phone (860) 721-9199 – Fax Benadryl (Diphenhydramine) Dosing Chart *Ages 6 months & above* Dose every 6 hours: Dose for hives and/or itching. In general, once hives have started, you should continue regular dosing until there have not been hives for the entire day. Benadryl (Diphenhydramine) Liquid: Chewable Tablets: Tablets: Weight: 12.5mg/5ml 12.5mg each 25 mg each 17-21 pounds ¾ tsp. (3.75ml) Use Liquid Use Liquid Use 22-32 pounds 1 tsp. (5ml) 1 tablet Liquid or Chews Use 33-42 pounds 1 ½ tsp. (7.5ml) 1 ½ tablets Liquid or Chews 43-53 pounds 2 tsp. (10ml) 2 tablets 1 tablet 54-64 pounds 2 ½ tsp. (12.5ml) 2 ½ tablets 1 tablet 65-75 pounds 3 tsp. (15ml) 3 tablets 1 tablet 76-86 pounds 3 ½ tsp. (17.5ml) 3 ½ tablets 1 tablet >86 pounds 4 tsp. (20ml) 4 tablets 2 tablets EDUCATION ON CALL Administering Medicine Safely When your child isn’t feeling well, you want to relieve their discomfort as quickly as possible. Be prepared with information that can help you understand the differences between pediatric pain relievers and fever reducers, and how to administer them safely. Always read the label 1. Active ingredient: Ingredient that makes the medicine work 2. Uses: Symptoms the medicine treats 3. Directions: The amount of medicine to give and how often Know the difference TYLENOL® MOTRIN® Active ingredient: Acetaminophen Active ingredient: Ibuprofen • Treats pain & fever • Treats pain & fever • Gentle on tummies • Lasts up to 8 hours • Dosing available from your pediatrician for • Can be used for children 6 months of age or older children 6 months and younger Never give aspirin to children.
    [Show full text]
  • Over-The-Counter (OTC) Medications
    Over-the-Counter (OTC) Medications Helpful Tips • Choose products that target your specific symptoms, rather than combination products that treat many symptoms that you may not have. See below. • Be cautious of doubling up on the same ingredients (for example, Tylenol is in many products). • Take extra care when using “PM” products, as they may have serious side effects. • Always read the product labels for important dosing and precaution information. - Doses may differ for adults and children - Many products have age limitations - Most products have a maximum number of days that they should be used OverO-thever--counterthe-counter options options Over-the-Counter Options CombinationCombination Products: Products: treat multipletreat multiple symptoms symptoms Combination products often results in overtreating because you’re taking medications for Combination Products: Treat multiple symptoms Combination• products often results in overtreating because you’re taking medications for • symptoms that you do not have. • Combination products often result in overtreating because you’re taking medications for symptoms that you do not have. Instead,Over choose-the- counteran over-the options-counter p roduct that targets your specific symptoms with symptoms that you do not have. •Instead, choose an over-the-counter product that targets your specific symptoms with • ingredients only for those symptom • Instead, choose an over-the-counter product that targets your specific symptoms with Combination Products:ingredients treat multipleonly for thosesymptoms
    [Show full text]
  • Transdermal Nicotine Maintenance Attenuates the Subjective And
    Neuropsychopharmacology (2004) 29, 991–1003 & 2004 Nature Publishing Group All rights reserved 0893-133X/04 $25.00 www.neuropsychopharmacology.org Transdermal Nicotine Maintenance Attenuates the Subjective and Reinforcing Effects of Intravenous Nicotine, but not Cocaine or Caffeine, in Cigarette-Smoking Stimulant Abusers 1 1 ,1,2 Bai-Fang X Sobel , Stacey C Sigmon and Roland R Griffiths* 1Department of Psychiatry and Behavioral Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA; 2Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA The effects of transdermal nicotine maintenance on the subjective, reinforcing, and cardiovascular effects of intravenously administered cocaine, caffeine, and nicotine were examined using double-blind procedures in nine volunteers with histories of using tobacco, caffeine, and cocaine. Each participant was exposed to two chronic drug maintenance phases (21 mg/day nicotine transdermal patch and placebo transdermal patch). Within each drug phase, the participant received intravenous injections of placebo, cocaine (15 and 30 mg/70 kg), caffeine (200 and 400 mg/70 kg), and nicotine (1.0 and 2.0 mg/70 kg) in mixed order across days. Subjective and cardiovascular data were collected before and repeatedly after drug or placebo injection. Reinforcing effects were also assessed after each injection with a Drug vs Money Multiple-Choice Form. Intravenous cocaine produced robust dose-related increases in subjective and reinforcing effects; these effects were not altered by nicotine maintenance. Intravenous caffeine produced elevations on several subjective ratings; nicotine maintenance did not affect these ratings. Under the placebo maintenance condition, intravenous nicotine produced robust dose-related subjective effects, with maximal increases similar to the high dose of cocaine; nicotine maintenance significantly decreased the subjective and reinforcing effects of intravenous nicotine.
    [Show full text]